Skip to main content

Abstract

Understanding and being able to apply the principles of pharmacology is a key component in the treatment of patients’ medical conditions. Pharmacokinetics describes the interaction of the body upon a drug and its pathway as it moves across cell membranes. Pharmacodynamics encompasses the relationship between drug concentration and the effect within the human body. In addition to pharmacokinetics and pharmacodynamics leading to individual responses to drug therapy, exploration of the genetic influence continues to be an area of intense research. Each individual has his or her own unique genetic code and how individual genetic variations affect drug response is referred to as pharmacogenetics. While the ability to take one’s medication as directed seems like a simple concept, in actuality, adherence is complex and influenced by many factors. Medication selection and route of administration may be influenced by available formulation options and concomitant conditions. These concepts are reviewed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 389.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 499.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. van den Anker J. Developmental pharmacology. Dev Disabil Res Rev. 2010;16:233–8.

    Article  PubMed  Google Scholar 

  2. Buxton I, Benet L. Pharmacokinetics: The dynamics of drug absorption, distribution, action and elimination. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New-York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=16658148

  3. Kearns G, Abdel-Rahman S, Alander S, Blowey D, Leeder J, Kaufmann R. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.

    Article  CAS  PubMed  Google Scholar 

  4. Nahata M, Taketomo C. Pediatrics. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L, editors. Pharmacotherapy. A pathophysiological approach. 8th ed. New York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=7967222

  5. Rempel G, Coates J. Special considerations for medication use in children with developmental disabilities. Phys Med Rehabil Clin N Am. 1999;10(2):493–509.

    CAS  PubMed  Google Scholar 

  6. American Academy of Pediatrics, Committee on Drugs. Alternative routes of drug administration-advantages and disadvantages (subject review). Pediatrics. 1997;100(1):143–52.

    Article  Google Scholar 

  7. Winter M. Clinical pharmacokinetics. In: Young L, Koda-Kimble M, editors. Applied therapeutics, the clinical use of drugs. 6th ed. Vancouver: Applied Therapeutics; 1995. p. 1–19.

    Google Scholar 

  8. Bauer L. Clinical pharmacokinetic and pharmacodynamic concepts. In: Bauer L, editor. Applied clinical pharmacokinetics. 2nd ed. New York: McGraw-Hill; 2008. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=3517025

  9. Bauer L. Clinical pharamcokinetics and pharmacodynamics. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L, editors. Pharmacotherapy, a pathophysiological approach. 8th ed. New York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=7966662

  10. Holford N. Pharmacokinetics and pharmacodynamics: Rational dosing and the time course of drug action. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw-Hill; 2012. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=7966662

  11. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy. 1995;15(6 Pt 2):84S–99.

    CAS  PubMed  Google Scholar 

  12. Correia M. Drug biotransformation. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw-Hill; 2012. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=55820543

  13. Anderson G, Lynn A. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy. 2009;29(6):680–90.

    Article  CAS  PubMed  Google Scholar 

  14. Blumenthal D, Garrison J. Pharmacodynamics: Molecular mechanisms of drug action: Introduction. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New-York: McGraw-Hill; 2011. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aid=16658452

  15. Von Zastrow M. Drug receptors and pharmacodynamics. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw-Hill; 2012. http://0-www.accesspharmacy.com.libcat.ferris.edu/content.aspx?aID=55820130

  16. Galinkin J, Demmer L, Yaster M. Genetics for the pediatric anesthesiologist: a primer on congenital malformations, pharmacogenetics, and proteomics. Anesth Analg. 2010;111:1264–74.

    Article  PubMed  Google Scholar 

  17. Roden D, Altman R, Benowitz N, Flockhart D, Giacomini K, Johnson J, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006;145:749–57.

    Article  PubMed  Google Scholar 

  18. Leeder J. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am. 2001;48(3):765–81.

    Article  CAS  PubMed  Google Scholar 

  19. Evans W, McLeod H. Pharmacogenomics – drug disposition, drug targets and side effects. N Engl J Med. 2003;348(6):538–49.

    Article  CAS  PubMed  Google Scholar 

  20. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529–37.

    Article  PubMed  Google Scholar 

  21. Ingleman-Sundberg M, Evans W. Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics. 2001;11:553–4.

    Article  Google Scholar 

  22. Lexi-Comp, Inc. (Lexi-Drugs®). Lexi-Comp.

    Google Scholar 

  23. Blum M, Grant D, McBride W, Heim M, Meyer U. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9:193–203.

    Article  CAS  PubMed  Google Scholar 

  24. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400–4.

    Article  CAS  PubMed  Google Scholar 

  25. Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189–99.

    Article  CAS  PubMed  Google Scholar 

  26. Madian A, Wheeler H, Jones R, Dolan M. Relating human genetic variation to variation in drug responses. Trends Genet. 2012;28(10):487–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. KCNE2. Genetics Home Reference. URL: http://ghr.nlm.nih.gov/gene/KCNE2

  28. US Food and Drug Administration, US Department of Health and Human Services. Drugs; Table of pharmacogenomic biomarkers in drug labeling. URL: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacoge netics/ucm083378.htm

  29. Pirmohamed M, Burnside G, Eriksson N, Jorgensen A, Toh C, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369(24):2294–303.

    Article  CAS  PubMed  Google Scholar 

  30. Kimmel S, French B, Kasner S, Johnson J, Anderson J, Gage B, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369(24):2283–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med. 2013;369(24):2345–6.

    Article  CAS  PubMed  Google Scholar 

  32. Ma J, Lee K, Kuo G. Clinical application of pharmacogenomics. J Pharm Pract. 2012;25(4):417–27.

    Article  PubMed  Google Scholar 

  33. O’Donnell P, Bush A, Spitz J, Danahey K, Saner D, Das S, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Nature. 2012;92(4):446–9.

    Google Scholar 

  34. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  35. Haynes B, McDonald H, Garg A. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–3.

    Article  PubMed  Google Scholar 

  36. Matsui D. Current issues in pediatric medication adherence. Pediatr Drugs. 2007;9(5):283–8.

    Article  Google Scholar 

  37. Dusing R, Lottermoser K, Mengden T. Compliance with drug therapy: new answers to an old question. Nephrol Dial Transplant. 2001;16:1317–21.

    Article  CAS  PubMed  Google Scholar 

  38. Staples B, Bravender T. Drug compliance in adolescents assessing and managing modifiable risk factors. Pediatr Drugs. 2002;4:503–13.

    Article  Google Scholar 

  39. Winnick S, Lucas D, Hartman A, Toll D. How do you improve compliance? Pediatrics. 2005;115(6):e718–24.

    Article  PubMed  Google Scholar 

  40. Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.

    Article  CAS  PubMed  Google Scholar 

  41. Erhardt L. The essence of effective treatment and compliance is simplicity. Am J Hypertens. 1999;12(suppl):105S–10.

    Article  CAS  PubMed  Google Scholar 

  42. Ickovics J, Meade C. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14:309–18.

    Article  CAS  PubMed  Google Scholar 

  43. Shah B, Hajjar E. Polypharmacy, adverse drug reactions and geriatric syndromes. Clin Geriatr Med. 2012;28:173–86.

    Article  PubMed  Google Scholar 

  44. Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics. 2013;132(5):833–40.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Hanlon J, Schmader K, Samsa G, Weinberger M, Uttech K, Lewis I, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.

    Article  CAS  PubMed  Google Scholar 

  46. Gokula M, Holmes H. Tools to reduce polypharmacy. Clin Geriatr Med. 2012;28:323–41.

    Article  PubMed  Google Scholar 

  47. Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28:159–72.

    Article  PubMed  Google Scholar 

  48. Mula M, Trimble M. Antiepileptic drug-induced cognitive adverse effects, potential mechanisms and contributing factors. CNS Drugs. 2009;23(2):121–37.

    Article  CAS  PubMed  Google Scholar 

  49. Tutuian R. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. 2010;24(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  50. Clayden G. Management of chronic constipation. Arch Dis Child. 1992;67:340–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Green LB, Hurvitz EA. Cerebral palsy. Phys Med Rehabil Clin N Am. 2007;18(4):859–82.

    Article  PubMed  Google Scholar 

  52. Tilton A, Vargus-Adams J, Delgado MR. Pharmacologic treatment of spasticity in children. Semin Pediatr Neurol. 2010;17(4):261–7.

    Article  PubMed  Google Scholar 

  53. Fruen BR, Mickelson JR, Louis CF. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem. 1997;272:26965–71.

    Article  CAS  PubMed  Google Scholar 

  54. Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374%26sectionid=41266218

  56. Mihic S, Harris A. Hypnotics and sedatives. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374&sectionid=41266223

  57. Meyer J. Pharmacotherapy of psychosis and mania. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374&sectionid=41266222

  58. McNamara J. Pharmacotherapy of epilepsies. In: Brunton K, Chabneer B, Knollman B, editors. Goodman and Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011. URL: http://0-accesspharmacy.mhmedical.com.libcat.ferris.edu/content.aspx?bookid=374&sectionid=41266227

  59. Food and Drug Administration. URL: www.fda.gov

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cynthia Feucht Pharm.D, BCPS, CGP .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Feucht, C., Patel, D.R., Bovid, K.M. (2016). Principles of Pharmacology. In: Rubin, I.L., Merrick, J., Greydanus, D.E., Patel, D.R. (eds) Health Care for People with Intellectual and Developmental Disabilities across the Lifespan. Springer, Cham. https://doi.org/10.1007/978-3-319-18096-0_141

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18096-0_141

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18095-3

  • Online ISBN: 978-3-319-18096-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics